Baxter International Inc. (BAX) and Halozyme Therapeutics (HALO) announced Monday morning that the FDA has requested additional information to complete its review of the HyQ Biologics License Application.
Baxter International has gapped open sharply lower Monday and is now down 3.38 at $54.65. The stock has dropped to a 2 1/2 month low and has fallen below its 200-day moving average.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org